Genfit (FRA:XUPB) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:XUPB Genfit SA FRA:XUPB
59 GF Score
Price €6.15
GF Value €4.21
! 10 Warning Signs
View Full Analysis

What is Genfit Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:XUPB
59GF Score
Genfit SA FRA:XUPB
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genfit (FRA:XUPB) Overvalued in 2026?

Based on GuruFocus' analysis, Genfit stock appears to be overvalued. The current stock price of €6.15 is trading 46.1% above its estimated GF Value™ of €4.21.

Key valuation signals for FRA:XUPB:

  • Dividends Received:
  • GF Value™: €4.21 vs. price of €6.15 (46.1% above fair value)
  • GF Score™: 59/100 with 10 warning signs

No single metric tells the full story. See the FRA:XUPB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genfit Business Description

Address 885, Avenue Eugene Avinee, Parc Eurasante, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements to fund the further development of its products. It has one segment, the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
59GF Score

Get the complete analysis for FRA:XUPB

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.15
Price
€4.21
GF Value